AVEO Pharmaceuticals, Inc.
TREATMENT OF CHRONIC KIDNEY DISEASE AND OTHER RENAL DYSFUNCTION USING A GDF15 MODULATOR
Last updated:
Abstract:
The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.
Status:
Application
Type:
Utility
Filling date:
2 Nov 2018
Issue date:
26 Sep 2019